Skip to content
DE

EnfuvirtideAntiviral peptide medicine

Enfuvirtide blocks a step that HIV uses to enter cells. Its evidence concerns combination treatment, particularly in treatment-experienced people, rather than a stand-alone cure or general antiviral effect.

What is Enfuvirtide?

Enfuvirtide is an HIV fusion inhibitor used within combination antiretroviral treatment, particularly studied in treatment-resistant infection.

How it works

It binds a region of HIV gp41 involved in fusion with the host-cell membrane, blocking an entry step rather than a viral enzyme inside the cell.

Effects studied

HIV viral-load control

Pivotal research studied enfuvirtide with an optimised background regimen. 1 2

Evidence: The clinical outcome reflects combination treatment; it is not evidence for stand-alone use or activity against unrelated viruses.

What does the evidence show?

Combination antiretroviral trials; archived references retained

Stopping an entry step

HIV must fuse its envelope with a host cell membrane to deliver its contents. Enfuvirtide binds a region of the viral gp41 protein involved in this process. This gives it a mechanism distinct from medicines that inhibit viral enzymes after entry.

Why resistance changes the question

People with treatment-resistant HIV may need a regimen containing active medicines from different classes. The pivotal research studied enfuvirtide alongside an optimised background regimen. A fall in viral load in that setting describes the combined treatment strategy, not the peptide acting in isolation.

The practical burden matters

Enfuvirtide is administered by injection, and local injection-site reactions are a prominent issue. For a continuing treatment, discomfort and adherence influence real-world value alongside antiviral activity. Hypersensitivity and other reported safety concerns also require assessment within the person’s broader clinical situation.

A specific antiviral, not a universal one

A mechanism involving HIV fusion does not establish activity against unrelated viruses or support use for nonspecific immune support. Product availability has changed over time and needs a current country-level check. Choosing treatment requires resistance testing and assessment of the complete regimen, tolerability and access. An older approval does not establish that a medicine is the preferred option today.

Safety & status

Injection-site reactions can create a substantial treatment burden. Hypersensitivity and other safety concerns require clinical assessment. Current country-level availability and the full resistance-informed regimen also matter.

Country and product status

Country-specific product availability and authorisation require a separate current check.

Frequently asked questions

Was enfuvirtide studied alone?

The pivotal treatment-resistant HIV research used it alongside an optimised background regimen. 1 2

Does its fusion mechanism make it broadly antiviral?

No. A target in HIV gp41 does not establish activity against unrelated viruses.

Sources

This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.

  1. Enfuvirtide · retained archive reference Archive research lead · Retained archive reference; not independently checked for this draft
  2. Enfuvirtide · retained archive reference Archive research lead · Retained archive reference; not independently checked for this draft
Research provenance

This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.